For instance, treatment of metastatic melanoma, cholangiocarcinoma, and glioblastoma cells with the widely used active site MALT1 inhibitor MI-2 abrogates proliferation, migration, and invasion, reduces cell viability, and diminishes tumor growth and metastasis in vivo via downregulation of the NF-κB pathway [86,91,92]. This evidence concerns the gene NFKB1 and neoplasm.